The Multiple Myeloma Research Foundation (MMRF) has developed innovative, collaborative business models to reshape the R&D enterprise with the single-minded focus of accelerating the development of new treatments for patients to extend their lives and lead to a cure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dilts, D. & Sandler, A. J. Clin. Oncol. 24, 4545–4551 (2006).
Wear, S. et al. Proc. American Society of Hematology, San Diego, CA, Dec. 2011 (Abstract #1024)
Chapman, M.A. et al. Nature 471, 467–472 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Giusti, K. The Multiple Myeloma Research Foundation's evolving focus on drug R&D. Nat Biotechnol 30, 600–603 (2012). https://doi.org/10.1038/nbt.2297
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2297
This article is cited by
-
Next-generation proteasome inhibitor approved in multiple myeloma
Nature Biotechnology (2012)
